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Abstract
Background: Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial
growth factor in different human cancers. This study assessed the efficacy of endostatin combined with concurrent
chemoradiotherapy of non-small cell lung cancer (NSCLC).
Methods: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG)
performance status 0-l, and adequate organ function were treated with 60–66 Gy thoracic radiation therapy over
30–33 fractions concurrent with weekly 7.5 mg/m2 endostatin for 14 days, 50 mg/m2 paclitaxel, and 2 mg/mL/min
carboplatin over 30 min. Patients were then treated with 7.5 mg/m2 endostatin for 14 days, 150 mg/m2 paclitaxel, and
5 mg/mL/min carboplatin every 3 weeks for 2 cycles as the consolidation treatment. The objective response rate was
recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated
using the National Cancer Institute (NCI) Common Toxicity Criteria.
Results: Six patients were unable to complete the consolidation treatment (4 pulmonary toxicity, 1 tracheoesophageal
fistulae, and 1 progressive disease). Seventeen patients were included for data analysis. Specifically, one (5.9 %) patient
had a complete response and 12 (70.6 %) had a partial response, whereas two patients had stable disease and the
other two had disease progression. The overall response rate was 76 % (95 % confidence interval [CI], 51 %–97 %). The
median progression-free survival was 10 months (95 % CI, 7.6–12.3 months), and the median overall survival was
14 months (95 % CI, 10.7–17.2 months). Early 10 patients who completed the treatment regimen showed that four
patients experienced grade III pulmonary toxicity a few months after chemoradiotherapy, leading to the early closure
of the trial according to the study design.
Conclusions: The reslult of concurrent endostatin treatment with chemoradiotherapy in locally advanced unresectable
NSCLC did not meet the goal per study design with unacceptable toxicity. The real impact of endostatin as the
first-line treatment combined with chemoradiotherapy on the survival of NSCLC patients remains to be determined.
(NCT 01158144).
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Background
Lung cancer is the most significant worldwide health
problem, and it accounted for 1.6 million new cancer
cases and 1.4 million cancer-related deaths worldwide in
2008 [1]. Histologically, lung cancer can be classified pri-
marily as small cell lung cancer or non-small cell lung
cancer (NSCLC), and up to 85 % of all lung cancer cases
are NSCLC. To date, more than one-third of NSCLC
cases are still diagnosed at the advanced stages of disease
when curable surgery is no longer an option. A standard
treatment for patients with inoperable locally advanced
NSCLC is the use of concurrent chemoradiotherapy
(CRT) [2, 3]. Clinically, chemoradiotherapy often fails to
control NSCLC progression, and many patients die of
recurrent disease. Thus, novel treatment strategies that
effectively control NSCLC are urgently needed.
To this end, many research efforts have focused on de-
veloping novel treatment regimens to target tumor angio-
genesis. Cancer tissues consist of a population of rapidly
dividing and growing cancer cells, and to support tumor
aggression, tumor cells secrete various growth factors [e.g.,
basic fibroblast growth factor (bFGF) and vascular endo-
thelial growth factor (VEGF)] to induce tumor angiogen-
esis in order to increase the supply of oxygen and other
essential nutrients within tumor tissues [4]. Endostatin, a
peptide identified in 1996, can specifically inhibit the
activity of bFGF and VEGF to suppress tumor-related
neovascular endothelial cells and induce cancer cell apop-
tosis [5]. A previous clinical trial has positively evaluated
endostatin application in NSCLC [6]. Two additional ran-
domized phase II studies in China also evaluated endosta-
tin as the first-line therapy against advanced NSCLC and
showed that endostatin together with platinum-based
chemotherapy might increase response rates and pro-
long progression-free survival (PFS) and overall survival
(OS) in NSCLC patients [7, 8]. Moreover, previous data
on preclinical lung cancer models demonstrated that
endostatin used as an adjuvant to radiation can signifi-
cantly enhance the antitumor efficacy of radiotherapy
in lung cancer cells [9, 10]. Taken together, previous stud-
ies have shown in vitro and in vivo that endostatin has
anti-tumor activity as both an adjuvant and a concurrent
treatment for different human cancers. Thus, in this phase
II clinical trial, we assessed the efficacy of combined endo-
statin treatment with concurrent chemoradiotherapy on
patients with unresectable stage III NSCLC.
Methods
Patient eligibility
The study protocol was approved by the institutional
review board of Zhejiang Cancer Hospital (#200934) on
September 1, 2009 and registered in ClinicalTrials.gov
(#NCT01158144), May 13, 2010. Patients provided written
informed consent to participate in this clinical trial and
were informed of the investigational nature of the trial.
In this clinical study, we prospectively recruited 19 pa-
tients with unresectable stage IIIA or IIIB NSCLC between
October 2009 and December 2011. All patients with
NSCLC (16 squamous and 3 adenosquamous cell lung
cancer) were histologically confirmed, and all patients had
Eastern Cooperative Oncology Group (ECOG) perform-
ance status 0 or l and adequate organ functions. Tumor
lymph node metastasis was diagnosed by either histology,
positron emission tomography with lymph node >0.5 cm
in size, or computed tomography (CT) scan of 1-cm
lymph nodes. The patients had no history of previous
chemotherapy, radiotherapy, or surgical resection. Lung
function of a forced expiratory volume in 1 s (FEV1)
≥1.5 L was also met, and the patients did not receive
any full dose of anticoagulant or have any other patho-
logic conditions. None of the patients had a fine
needle/core biopsy or mediastinoscopy within 7 days
before treatment.
Treatment of patients
The detailed treatment plan is summarized in Fig. 1. All
patients received the concurrent CRT regimen, i.e.,
chemotherapy consisting of weekly 50 mg/m2 paclitaxel
over 1 h, weekly 2 mg/mL/min carboplatin over
30 min, and 7.5 mg/m2 endostatin over 3 h infusion be-
tween days 1 and 14 and between days 22 and 35. Radi-
ation therapy was field arranged and determined by 3D
or IMRT planning at the primary lesion and involvement
of metastatic lymph nodes, and was prescribed at 60–
66 Gy and given in 30–33 fractions at 200 cGy/day, 5 days
a week without interruption. After 4–7 weeks of comple-
tion of radiation therapy, patients without progressive
disease according to the Response Evaluation Criteria
in Solid Tumors (RECIST) were then given 150 mg/m2
paclitaxel and 5 mg/mL/min carboplatin on day 1 and
7.5 mg/m2 endostatin between days 1 and 14 every 3 weeks
for two cycles as the consolidation treatment.
Toxicity evaluation and treatment modifications
In this clinical trial, we followed the National Cancer
Institute (NCI) Common Toxicity Criteria version 3.0
to assess treatment-related toxicities and adverse events
[http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm]. In brief, if the absolute granulocyte
count was <1.5 × 109/L, and/or the platelet count was <75 ×
109/L, chemotherapy was delayed. Dose delays up to 2 weeks
from day 1 of the current cycle were permitted for recovery
from adverse events. Paclitaxel and carboplatin infusion was
recommenced with a 25 % dose reduction if patients
experienced higher than grade II hematological toxicity
during the previous treatment cycle. The dosages of pacli-
taxel and carboplatin were reduced to 50 % if the patients
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still suffered grade III hematological toxicity. A maximum
of two dose reductions were permitted. Furthermore,
granulocyte colony-stimulating factor at a dose of 5 μg/
kg was recommenced for treating neutropenic events.
Following the first dose of endostatin, toxicity was
assessed weekly in all patients, and special attention
was given to monitoring blood pressure, bleeding, car-
diovascular events, esophagitis, and tracheoesophageal/
bronchial fistulae. Modification of the endostatin dose
due to drug toxicity could be made at the discretion of
physicians. If one or more study drugs were discontin-
ued, further treatment with the remaining drugs was
allowed in the absence of disease progression.
Patient evaluation and follow-up
All patients were evaluated before participation in this
clinical trial according to medical history, physical exam,
PS, laboratory tests, pulmonary function test, EKG, and
MRI or CT scan of the brain, chest, liver, and adrenal
glands. During CRT and consolidation treatment, complete
blood counts were assessed weekly. Patients’ history,
physical exam results, and chemistries were re-assessed
prior to each treatment cycle. Once endostatin was
started, weekly toxicity assessment was required and
continued until 60 days after discontinuation of endo-
statin or until all adverse events had resolved. Treat-
ment response was assessed at the end of CRT and
carboplatin/paclitaxel/endostatin consolidation treatment
and then every 2–3 months for 2 years and every 6 months
until 5 years.
Statistical analyses
This is a prospective phase II study at a single institu-
tion, and the primary end point of the trial was to evalu-
ate the response rate and toxicity of this concurrent
radiotherapy and chemotherapy regimen. The secondary
end point was PFS and OS of the patients with unre-
sectable locally advanced NSCLC. This clinical trial was
designed to measure a response rate [complete re-
sponses (CRs) and partial responses (PRs)] of 85 % com-
pared to a minimal, clinically meaningful response rate
of 70 %. Using an alpha = 0.05 and a power of 80 %, the
target number of patients required to achieve an 85 %
CR plus PR rate was 20 patients according to a previous
study [11].
Given the known risks of concurrent chemoradio-
therapy, a toxicity analysis was planned after 10 pa-
tients had completed all treatment regimes. Toxicity
was assessed as unacceptable if 4 or more of these 10
patients experienced at least grade III esophageal or
pulmonary toxicity.
PFS was calculated from the day of initiation of
treatment to the date of disease progression, death
or until the last follow-up, whereas OS was calculated
from the first day of CRT until death or until the last
follow-up. The survival curves were calculated using
the Kaplan–Meier method. The considered variables
included: age, gender, histopathology, smoking status
(cigarettes/year), and stage. All statistical analyses
were performed using SPSS software, Version 19.0
(SPSS Inc., Chicago, IL).
Fig. 1 Treatment schedules of the patients
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Results
Patient characteristics
This study was opened in October 2009 and closed in
December 2011 according to the protocol definition, i.e.,
early 10 patients who completed treatment, including
four or more patients with at least grade III pulmonary
toxicity a few months after the CRT, thus leading to the
early closure of the trial according to the study design..
The characteristics of these 19 assessable patients are
shown in Table 1. In brief, there were 16 patients with
squamous cell carcinoma and a higher proportion of
male patients with stage IIIB. Seventeen patients com-
pleted the CRT, whereas six patients were unable to
complete the consolidation treatment (4 due to pulmon-
ary toxicity, 1 due to tracheoesophageal fistulae, and 1
due to progressive disease).
Treatment efficacy
Nineteen patients had measurable disease at baseline.
Response was not assessable in two (10.5 %) patients
due to pulmonary toxicity and incompletion of the CRT
as planned. The objective tumor response for targeted
lesions was assessed and calculated 2–4 weeks after the
concurrent therapy. Seventeen patients were included in
data analysis. The overall response rate (CR + PR) was
76 % (95 % CI: 51 %–97 %), two (12 %) patients had
stable disease, and two (12 %) patients had disease pro-
gression (Table 2).
With a median follow-up time of 36 months, the me-
dian PFS was 10.0 months (95 % confidence interval
[CI]: 7.6–12.3 months), and the median OS was
14.0 months (95 % CI: 10.7–17.2 months; Fig. 2).
Treatment toxicity
Toxicities did occur during and after the concurrent
CRT or the consolidation treatment (Table 3). Specific-
ally, grades III or IV leukopenia or neutropenia was the
most common toxicity, occurring in 21 % and 26 % of
the patients, respectively. Moreover, 11 % patients devel-
oped Grade III/IV febrile neutropenia, 16 % patients had
grade III or IV esophagitis, and 26 % (5 episodes) had
grade III pneumonitis. In addition, there was one patient
with treatment-related tracheoesophageal/bronchial fis-
tulae (one patient developed grade III esophagitis during
concurrent CRT and then developed bracheoesophageal/
bronchial fistulae 19 days after the first cycle of consoli-
dation treatment).
Discussion
Chemotherapy has been successfully incorporated with
radiation to treat unresectable locally advanced NSCLC
with an acceptable toxicity. However, the treatment out-
come remains largely unsatisfactory, indicating that novel
agents to additively or synergistically enhance the action
of radiation against NSCLC are urgently needed. Thus,
our current study determined the efficacy of combined
endostatin treatment with concurrent chemoradiotherapy
in patients with unresectable stage III NSCLC. We found
that out of the 17 patients, 1 had a complete response and
12 had a partial response. Two patients had stable disease,
and another two had disease progression. The median PFS
was 10 months, and the median OS was 14 months. Early
10 patients who completed the treatment regimen showed
that four patients experienced grade III pulmonary tox-
icity, leading to the early closure of the trial according to
the study design. Thus, our current data showed that con-
current endostatin treatment with chemoradiotherapy in
locally advanced unresectable NSCLC did not meet the
goal per study design with unacceptable toxicity. The real
impact of endostatin as the first-line treatment combined
with chemoradiotherapy on the survival of NSCLC pa-
tients remains to be determined.
Currently, platinum-based CRT represents the standard
treatment regime for locally advanced NSCLC patients, al-
though the treatment efficacy is constrained by poor local
Table 1 Characteristics of patients
Characteristics No. of patients (N = 19)










UICC stage IIIA 5
IIIB 14
Table 2 Treatment efficacy in patients (N = 17)
Treatment efficacy No. of patients %
Response
Overall response rate 13 76.4
Disease control rate 15 88.2
Complete response 1 5.9
Partial response 12 70.6
Stable disease 2 11.7
Progressive disease 2 11.7
Survival
Median PFS (months) 10.0 (95 % CI: 7.6–12.3 months)
Median OS (months) 14.0 (95 % CI: 10.7–17.2 months)
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control and radiation-induced lung injury (RILI). To im-
prove the effect of the platinum-based CRT on NSCLC, a
number of clinical trials have been conducted, but similar
to our current study, the results suggest that the concomi-
tant treatment of patients with unresectable locally ad-
vanced NSCLC with endostatin, paclitaxel/carboplatin, and
radiotherapy does not show a significant clinical value.
The present study indicated that the overall response
rate (76 %; 95 % CI: 51 %–97 %) did not exceed the goal
per study design (85.0 %), and the toxicity analysis after
10 patients had completed treatment indicated that
four patients had grade III pulmonary toxicity. With a
median follow-up time of 36 months, the median PFS
was 10 months, and the median OS was 14 months. Simi-
lar results were reported by another phase II study
which assessed the activity and safety of weekly paclitaxel/
carboplatin vs. cisplatin/etoposide based CRT for patients
with unresectable IIIA/IIIB NSCLC. The overall response
rates (CR + PR) were 81.3 % in the paclitaxel/carboplatin
arm. With a median follow-up time of 46 months, the me-
dian OS was 13.5 months (95 % CI, 8.3–18.7 months) in
the paclitaxel/carboplatin group [12].
Furthermore, endostatin is a 20-kDa COOH-terminal
proteolytic fragment derived from the basement membrane
component of collagen XVIII. Endostatin is one of the most
potent inhibitors of angiogenesis. It was originally identified
from the supernatant of a murine hemangioendothelioma
cell line as an inhibitor of proliferation of endothelial cell
proliferation and of angiogenesis [13–15]. Indeed, several in
vitro and in vivo studies demonstrated that endostatin may
potentiate radiation [9, 10]. Thus, endostatin was designed
as a rational therapeutic agent combined with CRT for
treatment of unresectable locally advanced NSCLC. How-
ever, endostatin has toxicity concerns and may cause
development of tracheoesophageal/bronchial fistulae in
NSCLC patients, but this is generally an uncommon event
resulting from CRT of lung cancer. In a simultaneous and
ongoing study in limited stage SCLC, among 29 patients
there were 2 confirmed and 1 suspected episode of
Fig. 2 Kaplan–Meier survival curves of progression-free survival and overall survival of patients. The median progression-free survival was 10 months
(95 % CI, 7.6–12.3 months), and the median overall survival was 14 months (95 % CI, 10.7–17.2 months)
Table 3 Toxicity profile after treatment
Complications 0 I II III IV III + IV,
% (n)%(n) % (n) % (n) % (n) % (n)
Hematological toxicities
Anemia 32 (6) 26 (5) 32 (6) 11 (2) 0 11 (2)
Leukopenia 21 (4) 32 (6) 26 (5) 16 (3) 5 (1) 21 (4)
Neutropenia 16 (3) 32 (6) 26 (5) 21 (4) 5 (1) 26 (5)
Thrombocytopenia 26 (5) 42 (8) 21 (4) 5 (1) 5 (1) 11 (2)
Non-hematological toxicities
Nausea 37 (7) 37 (7) 16 (3) 11 (2) 0 11 (2)
Vomiting 47 (9) 32 (6) 11 (2) 11 (2) 0 11 (2)
Anorexia 53 (10) 26 (5) 11 (2) 5 (1) 5 (1) 11 (2)
Hemorrhage 90 (17) 5 (1) 5 (1) 0 0 0
Fatigue 37 (7) 32 (6) 26 (5) 5 (1) 0 5 (1)
ALT/AST 89 (15) 16 (3) 5 (1) 0 0 0
Arrhythmia 63 (12) 37 (7) 0 0 0 0
Esophagitis 26 (5) 37 (7) 16 (4) 11 (2) 5 (1) 16 (3)
Pneumonitis 21 (4) 26 (5) 26 (5) 26 (5) 0 26 (5)
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tracheoesophageal/bronchial fistulae [16, 17]. All 3 pa-
tients had grade III esophagitis during CRT and bevaci-
zumab treatment (another tumor angiogenesis inhibitor
that is a humanized monoclonal antibody directed against
VEGF). Subsequently, an additional patient developed a
fatal tracheoesophageal/bronchial fistulae during main-
tenance treatment. In an independent study of NSCLC
treatment, 2 of 5 patients developed tracheoesophageal/
bronchial fistulae during maintenance treatment with
chemotherapy and bevacizumab [17]. Both patients also
had severe esophageal toxicity after CRT and bevacizu-
mab. Therefore, together these results imply that severe
esophageal toxicity as a result of this treatment may pre-
dispose patients to the development of tracheoesophageal/
bronchial fistulae. In the Socinski trial, the rate of grade
III/IV esophagitis was 29 %, and one case of tracheoeso-
phageal/bronchial fistulae developed 3 months after CRT
[18]. One patient in our study developed grade III esopha-
gitis during concurrent CRT and then developed bra-
cheoesophageal/bronchial fistulae 19 days after the first
cycle of consolidation treatment. Thereafter, our study
was amended to exclude patients with grade III or higher
esophagitis from receiving endostatin. There were no cases
of bracheoesophageal/bronchial fistulae in two previously
randomized phase II studies in China in which endostatin
was given with platinum-based chemotherapy as first-line
treatment [7, 8].
However, our current data showed that it was difficult
to ascertain whether addition of endostatin was efficacious
in treating these patients and whether there was a synergy
of endostatin plus radiation therapy. The median PFS and
OS estimated at 10 and 14 months, respectively, were
similar to those of previous clinical trials of CRT alone
[1, 2, 4–6, 10, 16]. Whether the inconsistent schedule
of endostatin from other studies made our work unsuc-
cessful is worthy of more research. Our current study is
also limited by a small study population, and a future
study with more patients could help us to clarify the ef-
fects of endostatin on patients with unresectable locally
advanced NSCLC.
Conclusion
We were unable to successfully integrate endostatin into
concurrent CRT for unresectable locally advanced NSCLC
because of safety, and the data are insufficient to deter-
mine efficacy. There are numerous new molecularly tar-
geted agents that are of interest in the treatment of
NSCLC. Careful study design and close toxicity monitor-
ing is imperative to properly integrate their use in multi-
modality therapy.
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